Brianna Chrisman and Jordan Eizenga | Sep 1, 2022 | 10+ min read
Thirty years out from the start of the Human Genome Project, researchers have finally finished sequencing the full 3 billion bases of a person’s genetic code. But even a complete reference genome has its shortcomings.
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.
Saliva tests screen staff and students at University of Illinois; Study ranks species most susceptible to SARS-CoV-2 infection; COVID-19 clinical trials test drugs that inhibit kinin system
The effort to collect samples of DNA from diverse populations strives to overcome alleged public misunderstanding of its aims. SIDEBAR: For More Information MISINTERPRETED: "We need to show that this is just not a group of self-perpetuating insiders," says HGDP committee chairman Ken Weiss. Members of a National Research Council (NRC) panel evaluating the issues-both controversial and prosaic-surrounding the proposed Human Genome Diversity Project (HGDP) have their hands full. Conceived abou
Sidebar:Active and Recently Completed NIH ELSI Research Projects With passage of time and increasing political relevance, HGP branch's influence is on the rise among decision-makers Beginning this year, the component of the United States human genome initiative that has been sponsoring studies of the ethical, legal, and social implications of the massive genome effort's ground-breaking research will be reporting the first hard resul
Sidebar:Active and Recently Completed NIH ELSI Research Projects With passage of time and increasing political relevance, HGP branch's influence is on the rise among decision-makers Beginning this year, the component of the United States human genome initiative that has been sponsoring studies of the ethical, legal, and social implications of the massive genome effort's ground-breaking research will be reporting the first hard resul
Find the latest updates in this one-stop resource, including efficacy data and side effects of approved shots, as well as progress on new candidates entering human studies.